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Abstract: Orexins/hypocretins are neuropeptides formed by proteolytic cleavage of a precursor
peptide, which are produced by neurons found in the lateral hypothalamus. The G protein-coupled
receptors (GPCRs) for these ligands, the OX1 and OX2 orexin receptors, are more widely expressed
throughout the central nervous system. The orexin/hypocretin system has been implicated in many
pathways, and its dysregulation is under investigation in a number of diseases. Disorders in which
orexinergic mechanisms are being investigated include narcolepsy, idiopathic sleep disorders, cluster
headache and migraine. Human narcolepsy has been associated with orexin deficiency; however, it
has only rarely been attributed to mutations in the gene encoding the precursor peptide. While gene
variations within the canine OX2 gene hcrtr2 have been directly linked with narcolepsy, the majority
of human orexin receptor variants are weakly associated with diseases (the idiopathic sleep disorders,
cluster headache and polydipsia-hyponatremia in schizophrenia) or are of potential pharmacogenetic
significance. Evidence for functional interactions and/or heterodimerization between wild-type
and variant orexin receptors and opioid and cannabinoid receptors is discussed in the context of its
relevance to depression and epilepsy.
Keywords: orexin/hypocretin; OX1 orexin receptor; OX2 orexin receptor; homo-dimerization;
hetero-dimerization; opioid receptor; CB1 cannabinoid receptor; status epilepticus; feeding behavior;
sleep disorder
1. Introduction
The identification of a role for the orexins in narcolepsy contributed greatly to the field of orexin
genetics [1], but later findings related to other physiological functions, including genetic determinants,
also continue to propel this research [2]. The discovery of other functions of the orexinergic system
provided fresh rationales for exploring orexin pharmacogenetics. Since the development of orexinergic
drugs as sleep aids [3], it has become clear that there is a need for a greater understanding of the
Pharmaceuticals 2017, 10, 79; doi:10.3390/ph10040079 www.mdpi.com/journal/pharmaceuticals
Pharmaceuticals 2017, 10, 79 2 of 20
molecular pharmacology and pharmacogenomics of the orexins [4,5] and those systems they interact
with (eg. cannabinoid and opioid systems).
Orexin receptors belong to the rhodopsin family of the G protein-coupled receptor (GPCR)
superfamily. They have been described as able to interact with several heterotrimeric G protein
subfamilies as well as other proteins: resulting in a range of cellular responses as a result of the action
of ion channels, phospholipases and protein kinases. These signalling pathways control numerous
events such neuronal excitation, synaptic plasticity, and cell death [6–8]. The specific signalling features
in different cell types are likely determined by the expression profile of signalling components, signal
complexes and concurrent signals.
An outline of the molecular biology of the orexins, therefore, is introduced prior to examining
orexin pharmacology in the context of the functional interactions and/or di/oligomer formation that
may take place with other receptors such as the cannabinoid CB1 receptor. While sequencing projects,
such as the Exome Aggregation Consortium (http://exac.broadinstitute.org), have revealed that
variants of the OX1 and OX2 receptors are common in the population (Tables 1 and 2) most have only
been weakly associated with disease [2,5]. However, we acknowledge the possibility that co-expression
of variant receptors could result in a distinct pharmacology through functional interaction or as a result
of the formation of variant heterodimers. Our present focus, however, is to examine the evidence for
whether an orexin receptor functional interaction or heteromerization with cannabinoid CB1 receptors
contributes to some disease or pharmacogenetic phenotypes.
Table 1. OX1 orexin receptor variants investigated in disease. aa, amino acid; IC, intracellular loop;
SNP, single nucleotide polymorphism; TM, transmembrane helix [2].
OX1 aa Location SNP
Numbering/
Peyron
Numbering/
0lafsdottir Frequency Findings Ref.
167 Gly/Ser TM4 rs44603792 - 652 G/A 0002 - [9]
265 Leu/Met IC3 rs41501244 793 C/A - 0.001 - [10]
279 Arg/Gln IC3 rs7516785 - 989 G/A 0.008 - [9]
280 Gly/Ala
281 Arg/His
IC3
IC3
NP_001516
rs41439244 842 GIA 995 G/A 0.008 - [9,10]
408 Ile/Val C-term rs227 I933 1222 GIA 1375 G/A 0.56 - [9,10]
- - - - - - 1.4 X migraine [11]
- - - - - - 1.6 X mooddisorders [12]
- - - - - -
Polydipsia-
hyponatremia
in schizophrenia
[13,14]
- - - - - - Panic not linked [15]
Table 2. OX2 orexin receptor variants investigated in disease. aa, amino acid; IC, intracellular loop;
SNP, single nucleotide polymorphism; TM, transmembrane helix; CH, cluster headache [2].
OX2 aa Location SNP
Numbering/
Peyron
Numbering/
Olafsdottir Frequency Findings Ref.
10 Pro/Ser N-term rs41271310 28 C/T 352 C/T 0.003 0.003 Not linked [5,9,10]
- - - - - - with narcolepsy -
11 Pro/Thr N-term rs4127312 31 C/A 355 C/A 0.005 Not linked [5,9,10]
- - - - - - with narcolepsy -
193 Cys/Ser TM4 rs41381449 577 T/A - 0.002 - [10]
293 Ile/Val IC3 rs74720047 1201 G/A 0.002 - [9]
308 Ile/Val TM6 rs26533 922 G/A 1246 G/A 0.84 - [9,10]
- - - - - - Ile assoc. with panic [15]
- - - - - - Migraine notassociated [16]
- - - - - - Some association [17–19]
- - - - - - with CH -
- - - - - - No effect on triptanresponse [20]
401Thr/lle C-term rs41321149 1202 C/T 0.00012 - - [10]
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The Molecular Biology of the Orexins
In 1998, two research teams, the groups of De Lecea/Sutcfliffe and Sakurai/Yanagisawa,
independently published their discovery of novel neuropeptides which are exclusively expressed
in a small group of neurons localized to the lateral hypothalamus [21,22]. Based on their location
of origin and their sequence similarity to the gut hormone secretin, the De Lecea/Sutcfliffe group
named these peptides the hypocretins [22]. As the lateral hypothalamus is classically implicated in the
regulation of feeding, the Sakurai/Yanagisawa group assessed the role of this neuropeptide system
in appetite regulation. The positive experimental results lead Sakurai/Yanagisawa group to name
the peptides “orexins” after the Greek word for appetite [21]. Both groups in parallel identified the
precursor peptide, preprohypocretin or preproorexin (PPO), which undergoes cleavage to form two
smaller peptides, named hypocretin-1 and -2 or orexin-A and -B, respectively. The gene which encodes
PPO is located in human chromosome 17q21.2, and codes for a 131 amino acid peptide. The processed
mature neuropeptides orexin-A/hypocretin-1 and orexin-B/hypocretin-2 are 33 and 28 amino acids in
length, respectively.
The initial focus of the De Lecea/Sutcliffe group was to identify mRNA transcripts selectively
expressed in the hypothalamus [22]. Subsequent biological assays with the hypocretin-2/orexin-B
peptide showed neuroexcitatory activity on cultured hypothalamic neurons. The work of the
Sakurai/Yanagisawa group began with identifying peptide ligands for the putative orphan GPCR,
HFGAN72 [21]. Using extracts of rat brain and a cell-based reporter system, the receptor was found
to be activated by two peptides now known as orexin-A and -B. The orphan receptor found to have
highest affinity for orexin-A was named the OX1 receptor. By making use of homology, an additional
orexin receptor, OX2, was identified, and subsequently shown to have an equal affinity for both orexin
peptides. PPO mRNA distribution in the central nervous system (CNS) was mapped. The peptides
were found to be linked to the regulation of feeding behaviour based on evidence that they stimulated
food intake upon intracerebroventricular (ICV) administration, and that PPO mRNA expression in the
hypothalamus was increased upon fasting [21].
In addition to appetite, further studies established the role of the orexin/hypocretin system
in sleep and wakefulness cycles, metabolic regulation, stress responses, reward/addiction and
analgesia [6,21,23]. This complexity may reflect the widespread projections of orexin-producing
neurons within the CNS. The physiological role for the action of the orexin/hypocretin ligands at
the OX1 and OX2 receptors in the regulation of wakefulness and sleep is one example. Mignot and
co-workers isolated two hcrtr2 gene (the gene encoding OX2) frame-shift mutations responsible for
hereditary canine narcolepsy [24]. The frame-shifts both generate a premature stop codon. Truncated
receptor proteins do not traffic to the plasma membrane and remain localized in the cytoplasm [25].
Work by Yanagisawa and co-workers concurrently showed that knockout of the precursor peptide,
PPO, causes a narcoleptic phenotype in mice [26], which is stronger than the phenotype obtained
upon OX2 knockout [27]. In 2000, a profound decrease in the concentration of orexin-A was reported
in the cerebrospinal fluid (CSF) of human narcoleptics with cataplexy [28]. Only a few narcolepsy
patients have been shown to harbor T47G (Leu16Arg; the signal peptide) and –C22T (a.k.a. C3250T;
5’ untranslated region) variants of PPO [1,10]. Studies of the Leu16Arg PPO mutant suggested that the
processing and trafficking of the PPO are impaired [10], leading to subsequent problems with orexin
peptide maturation and release. Although rare, the pathogenic orexin peptide variants identified in
narcolepsy provided the rationale for the systematic study of orexin signalling in sleep disorders and
with respect to individual differences in drug response.
Orexins play a role in numerous physiological processes including sleep-wake cycle regulation and
the stimulation of feeding and regulation of energy homeostasis [29]. Additionally, exogenous orexins
stimulate a number of processes in the periphery of the body, including gastric acid secretion [30] and
glucocorticoid release [31,32], but the physiological significance of these is not known. Furthermore,
in mice, orexins influence the regulation of feeding and metabolism, and their expression is altered
by food deprivation [33,34]. Since there is very limited knowledge as to the effects of orexin peptide
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and receptor variants from heterologous expression systems, it is difficult to predict a role for these
processes in human disease. However, mutagenesis studies, modeling and orexin receptor crystal
structures have generated data upon which models of orexin receptor−ligand interaction may be
predicted [35–41].
2. Orexin Receptor Variants
Genetic variants of the orexin system have been identified. While amino acid sequence variants of
human OX1 and OX2 receptors (Figure 1) have not been implicated in human narcolepsy [1,10], genetic
variants of the OX1 and OX2 have been inconsistently and weakly associated with many CNS disorders
(Table l, Table 2) including sleep–wake dysregulation, polydipsia in schizophrenia [13,14], panic
disorder [15], mood disorders [12], migraine [11,16] and cluster headache [17–20,42]. The relevance of
human OX1 and OX2 receptor variants to disease states, identified originally using candidate gene
methodologies [5,43], is subject to confirmation by the methods of next generation sequencing [44]
that we pioneered to great effect in rare diseases such as Mabry syndrome [45]. Confirmation that
naturally occurring orexin variants are functional, let alone pathogenic, is debatable; however, study
of artificially created orexin receptor variants has provided insight into orexin receptor signalling that
may be relevant to functional interactions and/or heterodimerization with other receptors, such as the
cannabinoid CB1 receptor.Pharmaceuticals 2017, 10, 79 5 of 20 
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3.1. Coupling to G Proteins and Other Effectors 
An understanding of which orexin receptor is able to couple to which G protein is integral to a 
discussion of orexin pharmacology. The interaction of GPCRs with intracellular signal transducers 
usually takes place via the 2nd and/or 3rd intracellular loops and/or the C-terminus, however, it can 
sometimes result from interaction with the 1st intracellular loop [47]. Variations in these regions of 
orexin receptors could impact signalling directly by eliminating the necessary amino acid motifs or 
indirectly as a result of alterations in the receptor configuration [5,48,49]. Unfortunately, there are no 
data available on the actual G protein interaction sites in orexin receptors. However, β-arrestin (OX1 
and OX2) and dynein light chain Tctex-type 1 (OX1) are reported to couple to the orexin receptor 
C-terminus [50–52] and the Tyr phosphatase SHP-2 to the first intracellular loop (OX1) [53]. Based on the 
knowledge of GPCRs in general, some of the known variants, such as OX1265, OX1279, OX1280, OX1281, 
OX1408, OX2293, and OX2401 (Figure 1), could be implicated in G protein and other protein coupling.  
The orexin receptors bind their synthetic small molecular ligands in a partially hydrophilic, 
partially hydrophobic cleft [39,40]. The binding location of orexin peptides is not known, but is 
Figure 1. Alignment of the human OX1 and OX2 receptor amino acid sequences. The common
ild-type sequence of OX1 receptor is sho n (top) and the co on ild-type sequence of OX2 is
sho n (bottom). Arrows mark the location of known amino acid variants in relation to transmembrane
regions 1–7 (TM1–TM7). Alignment adapted fro Alscript output [46].
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3. Orexin Signalling
The potential for orexin receptors to functionally interact with other GPCRs or to homo- and/or
heterodimerize or oligomerize will be presented after we review the structure and function of wild-type
and variant the OX1 (Figure 2) and OX2 (Figure 3) receptors with respect to their signalling properties.
3.1. Coupling to G Proteins and Other Effectors
An understanding of which orexin receptor is able to couple to which G protein is integral to a
discussion of orexin pharmacology. The interaction of GPCRs with intracellular signal transducers
usually takes place via the 2nd and/or 3rd intracellular loops and/or the C-terminus, however,
it can sometimes result from interaction with the 1st intracellular loop [47]. Variations in these
regions of orexin receptors could impact signalling directly by eliminating the necessary amino acid
motifs or indirectly as a result of alterations in the receptor configuration [5,48,49]. Unfortunately,
there are no data available on the actual G protein interaction sites in orexin receptors. However,
β-arrestin (OX1 and OX2) and dynein light chain Tctex-type 1 (OX1) are reported to couple to the orexin
receptor C-terminus [50–52] and the Tyr phosphatase SHP-2 to the first intracellular loop (OX1) [53].
Based on the knowledge of GPCRs in general, some of the known variants, such as OX1265, OX1279,
OX1280, OX1281, OX1408, OX2293, and OX2401 (Figure 1), could be implicated in G protein and other
protein coupling.
The orexin receptors bind their synthetic small molecular ligands in a partially hydrophilic,
partially hydrophobic cleft [39,40]. The binding location of orexin peptides is not known, but is
assumed to take place in a similar manner, with the conserved peptide C-terminus entering into the
cleft. The N-terminus of the orexin peptide is then predicted to protrude from the cleft [41]. Thus, the
extracellular portions of the receptor may also contribute to peptide binding: a phenomenon deduced
from the OX2R structure that helped to develop a pharmacophore model of binding modes.
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Figure 2. Schematic of the OX1 receptor in the plasma membrane. Modified from Kukkonen et al. [23]; 
based on findings of Peyron et al. [10] and Olafsdottir et al. [9]. The variants marked with red arrows 
are: OX1167 Gly/Ser, OX1265 Leu/Met, OX1279 Arg/Glu, OX1280 Ala/Gly, OX1281 Arg/His, OX1408 
Ile/Val [2]. 
Figure 2. Schematic of the OX1 receptor in the plasma membrane. Modified from Kukkonen et al. [23];
based on findings of Peyron et al. [10] and Olafsdottir et al. [9]. The variants marked with red arrows
are: OX1167 Gly/Ser, OX1265 Leu/Met, OX1279 Arg/Glu, OX1280 Ala/Gly, OX1281 Arg/His, OX1408
Ile/Val [2].
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based on findings of Peyron et al. [10] and Olafsdottir et al. [9]. The variants marked with red arrows 
are: OX210 Pro/Ser, OX211 Pro/Thr, OX2193 Cys/Ser, OX2293 Ile/Val, OX2308 Ile/Val, and OX2401 
Thr/Ile [2]. 
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relevant for the OX210 Pro/Ser, OX211Pro/Thr, and OX2193Cys/Ser variants (Figure 1). 
In humans, polymorphisms in the N-terminal of OX2 include the Pro10Ser and Pro11Thr 
variants (Figures 1 and 2) described previously [5,62]. These variants may directly affect ligand 
binding, or indirectly affect ligand binding by altering receptor structure. However, the effects may 
be equivocal since the termini and loops connecting transmembrane helices are variable by 
comparison to the transmembrane core of rhodopsin family GPCRs. No mutagenesis studies have 
been conducted on orexin receptor N-termini. 
We review the pharmacology of the OX2 Pro10Ser variant before suggesting a rational for 
examining the OX2193 Cys/Ser (transmembrane helix 4 (TM4)) variant, the OX1167 Gly/Ser (TM4) 
variant and the less interesting OX2308 Ile/Val (TM6) variant [2]. Thompson et al. identified the OX2 
Pro11Thr variant in two DQB1*0602-negative excessive daytime sleepiness (EDS) patients and the 
OX2 Pro10Ser variant in a Tourette’s syndrome patient comorbid with attention deficit hyperactivity 
disorder (ADHD) and probable EDS (Figure 2) [5]. While the OX2 Pro10Ser and OX2 Pro11Thr 
variants were reported to be more common in human leukocyte antigen (HLA) DQB1*0602-negative 
narcoleptics compared with controls, Peyron et al. found these variants to be benign with respect to 
narcolepsy [10].  
These variants, however, are known to be rare in the general population (Table 1). The Pro10Ser 
variant (rs41271312) and the Pro11Thr variant (rs41271310) have been found to have approximate 
allele frequencies of 0.46% and 0.26%, respectively. In addition, even rarer polymorphisms have 
been identified at OX210 (a Pro10His substitution) and OX211 (a Pro11Ala substitution). The rarity of 
these variants in non-EDS populations suggested that their function should be evaluated in vitro [5]. 
Figure 3. Schematic of the OX2 receptor in the plasma membrane. Modified from Kukkonen et al. [23];
based on findings of Peyron et al. [10] and Olafsdottir et al. [9]. The variants marked with red arrows
are: OX210 Pro/Ser, OX211 Pro/Thr, OX2193 Cys/Ser, OX2293 Ile/Val, OX2308 Ile/Val, and OX2401
Thr/Ile [2].
In recombinant systems, the OX1 and OX2 receptors can easily couple to Gi/o, Gs, and Gq families
(G12/13 not assessed) and β-arrestin [50,51,54–57]. Similarly, in endogenous cells, orexin receptors
are likely capable of coupling to all these G protein families, but the interactions may be subject to
species-, tissue- and context-specific regulation [23]. For instance, OX2 receptors in human adrenal
cortex activate Gi, Gs, and Gq proteins [58]. Mixed orexin receptor populations in rat adrenal cortex or
hypothalamus couple to Gi, Go, Gs, and Gq [31]. Factors influencing signalling cascades have been
reviewed in detail elsewhere [6,7,23,59,60].
3.2. Post-Translational Modification
It is difficult to predict sites affecting receptor folding. In principle, however, every residue can
influence receptor folding at the local or a more general level. A major change in the amino acid size,
conformation, polarity and, especially, charge is likely to have a more pronounced effect. Glycosylation,
found on the extracellular orexin GPCR surfaces, could be affected by the availability of Asn and
Ser/Thr residues (and other sites in the putative consensus sequence) [2,61]. This could be relevant for
the OX210 Pro/Ser, OX211Pro/Thr, and OX2193Cys/Ser variants (Figure 1).
In humans, polymorphisms in the N-terminal of OX2 include the Pro10Ser and Pro11Thr variants
(Figures 1 and 2) described previously [5,62]. These variants may directly affect ligand binding, or
indirectly affect ligand binding by altering receptor structure. However, the effects may be equivocal
since the termini and loops connecting transmembrane helices are variable by comparison to the
transmembrane core of rhodopsin family GPCRs. No mutagenesis studies have been conducted on
orexin receptor N-termini.
We review the pharmacology of the OX2 Pro10Ser variant before suggesting a rational for
examining the OX2193 Cys/Ser (transmembrane helix 4 (TM4)) variant, the OX1167 Gly/Ser (TM4)
variant and the less interesting OX2308 Ile/Val (TM6) variant [2]. Thompson et al. identified the OX2
Pro11Thr variant in two DQB1*0602-negative excessive daytime sleepiness (EDS) patients and the
OX2 Pro10Ser variant in a Tourette’s syndrome patient comorbid with attention deficit hyperactivity
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disorder (ADHD) and probable EDS (Figure 2) [5]. While the OX2 Pro10Ser and OX2 Pro11Thr
variants were reported to be more common in human leukocyte antigen (HLA) DQB1*0602-negative
narcoleptics compared with controls, Peyron et al. found these variants to be benign with respect to
narcolepsy [10].
These variants, however, are known to be rare in the general population (Table 1). The Pro10Ser
variant (rs41271312) and the Pro11Thr variant (rs41271310) have been found to have approximate
allele frequencies of 0.46% and 0.26%, respectively. In addition, even rarer polymorphisms have been
identified at OX210 (a Pro10His substitution) and OX211 (a Pro11Ala substitution). The rarity of these
variants in non-EDS populations suggested that their function should be evaluated in vitro [5].
Variations in the sequence of the receptors may have effects apart from ligand binding. Previously,
Thompson et al. tested the functional significance of the Pro10Ser and Pro11Thr variants in transfected
COS-7 cells by measuring calcium elevation [5]. The results suggested that OX2 Pro10Ser variant
may be an example of a pharmacogenetic variant, though we cannot be sure that decreases in efficacy
and potency of orexin peptides at these variant OX2 receptors result from altered receptor expression
levels. However, there is a lack of conservation at these amino acid positions in the dog, rat and mouse
compared with the human wild-type: suggesting degeneracy at these positions. The conservation
of proline residues in general [63] and between species [64] suggests they may influence receptor
structure and function: possibly because proline residues are known to induce kinks in peptide chains
and disrupt α-helix and β-sheet structures.
3.3. Binding Pocket
Out of the 11 amino acid variants discussed in this review, the majority are not found within
the small molecule binding pocket [39,40]. Variant OX1167 harbors an alteration in TM4 close to the
intracellular region of the receptor, OX2193 results in an alteration in TM4 and OX2308 is located in TM6
(Figure 1). The latter two sites are less likely to affect ligand binding directly as they point away from
the binding cavity [39,40].
Variations of the orexin receptors have also been found in regions located outside the predicted
binding cavity that may also have consequences on the binding affinities measured in pharmacological
assays. These variants include the canine OX2 Glu54Lys mutation [24] which has been identified in
narcoleptic animals. It is possible that human variants of the N-terminal part of the receptor, such as at
OX210, may also influence binding indirectly due to conformational changes or the altered capacity of
receptors to homo- and heterodimerize.
The different roles of the two orexin peptides and the two orexin receptors have yet to be fully
explained. The respective roles of each peptide may be distinguished by expressing variant copies of
one or more orexin receptor polymorphism. In addition to ligand binding differences, co-expression of
the variant receptors in heterologous expression systems may allow identification of the domains in
each receptor that define homo- and heteromerization.
It is possible that phosphorylation events that regulate receptor desensitization in response to
ligand may be altered in a number of orexin receptor variants. Hydroxyl group-containing amino acids
Ser, Thr and Tyr are putative substrates for phosphorylation, while other amino acid variations may
affect the kinase consensus sequences [49]. Although these sites have not yet been targeted by point
mutagenesis studies, a Scansite (http://scansite.mit.edu/) motif search suggests that polymorphisms
at OX1167, OX1265, OX1279, OX1280, OX1408, and OX2401 (Figure 1) may be worth examining.
4. Modelling Orexin Receptor Hetero- and Homodimerization
Our discussion of the trafficking, ligand interaction and signalling of the orexin receptors must
consider the fact that GPCRs have been shown to dimerize. GPCRs were originally assumed to
exist as monomers: a view that has since been revised. More recent models tend to predict that
all functional GPCRs form dimers and oligomers [47,65]. Although orexin receptors may form
homodimers, heterodimers or even higher order oligomers [66–69], in recombinant expression systems,
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the number of monomers in each complex is difficult to assess. Manipulation of artificial and naturally
occurring variants of both OX1 and OX2 may provide a means of examining the receptor domains
necessary for multimerization. This strategy has been proposed to explain how a given phenotype,
such as asthma [70–73], may result from functional interactions and/or multimerizations of variant
cysteinyl leukotriene receptors [74].
With respect to OX1 and OX2, multimerization may influence pharmacological properties such as
the affinity for native and synthetic ligands and receptor localization and trafficking. Although there
is currently little physiological evidence of its significance, orexin pharmacology may be modulated
by the formation of OX1−OX2 heteromers. Since there is evidence of orexin OX1 and OX2 receptor
co-expression in at least some tissues [75], there is an opportunity for multimerization to take place.
While the many GPCRs expressed in any given cell represent potential heteromerization partners for
orexin receptors, it can be difficult to assess which are physiologically relevant.
The occasional inconsistencies in the results of homo- and heteromerization studies may reflect
limitations in the methods. The techniques most often used to assess dimerization are the resonance
energy transfer-based techniques, fluorescence resonance energy transfer (FRET) and bioluminescence
resonance energy transfer (BRET). However, they cannot be used to show or exclude higher order
complexes. While these methods are intended to assay the ability of receptors to form both homomeric
and heteromeric complexes, heteromers may have radically different pharmacology, signalling and
trafficking properties by comparison to homomeric ones [6,47]. Furthermore, FRET and BRET methods
do not easily indicate the efficiency of the complex formation. Resonance energy transfer efficiency
is dependent on the orientation and distance of the donor and acceptor. Any change in receptor
conformation, irrespective of whether it leads to receptor activation or not, may or may not influence
the efficiency of energy transfer [66,68,69,76,77]. Thus a difference in efficiency of energy transfer or
lack thereof may be of little predictive value.
The impact of naturally occurring variants, such as OX1408 Ile/Val and OX2401 Thr/Ile (Figure
l), on receptor dimerization is unknown; however, the polymorphic sites located within the receptor
C-terminus are adjacent to potential palmitoylation sites. Palmitoylation at the cytosolic end of
the third intracellular loop has been shown to promote dimerization of µ opioid receptors while
the oligomerization of β2 adrenoceptors occurs partially via the C-terminus [78,79]. However,
dimerization/oligomerization of other GPCRs may be dependent on other domains.
The importance of dimerization/oligomerization for most family A GPCRs is unclear [47,65].
Notable exceptions to this are the opioid receptors, whose pharmacology, signalling and trafficking
are significantly affected [80]. With respect to orexin receptors, early evidence suggested that
heterodimerization between CB1 cannabinoid receptors and OX1 may strongly potentiate orexin
receptor signalling. However, as we will discuss shortly, it is more likely that signal potentiation
depends on the ability of OX1 receptor signalling to elicit the production of CB1 receptor ligands:
thereby accounting for OX1 and CB1 receptor co-signalling [60,81–83]. While present evidence does not
preclude dimerization, it may suggest that the phenomenon is of limited physiological significance.
4.1. Evidence for Orexin Receptor Dimerization
The significance of disrupting motifs necessary for family A GPCR dimerization is not clear [84–86]
by comparison with evidence of the deleterious effects of disrupting motifs critical to family C GPCRs
dimerization [87,88]. One reason is the limited availability of anti-GPCR antibodies in general and
anti-orexin receptors in particular. It is common for antibodies to orexin receptors not to bind well or
to bind equally well to cells regardless of receptor expression.
The study by Xu et al. provided some evidence for ligand-enhanced OX1 homomerization.
Orexin-A was found to enhance di-/oligomerization, while antagonists reduced di-/oligomerization
below basal levels [66]. OX1 activation enhanced the FRET signal only under conditions of low
receptor expression. This is consistent with the idea that dimerization/oligomerization is a dynamically
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regulated process [86,89]. As has previously been reported for a number of family A GPCRs, the
process of heterodimerization has been implicated in maturation and cell surface trafficking [90,91].
It has been difficult, however, to prove any significant agonist-mediated impact on the process.
Since studies of the functional interactions between human orexin receptor variants are not available,
data on mouse orexin receptors may provide insight into the human system. Two splice variants of
the mouse OX2 receptor, OX2α and OX2β [92], differing by 17 amino acids in the C-terminus, have
been used to explore this phenomenon. Wang et al. demonstrated that splice variants heterodimerize
much more efficiently than homodimerize, as indicated by BRET studies [68]. Furthermore, functional
mOX2 heterodimers elevated intracellular Ca2+ and activated ERK.
Assuming the lessons from the heterodimerization of mouse OX2 receptor variants are relevant to
human orexin receptors, the data from Wang et al. [68] seems to suggest that, like the δ-opioid and
somatostatin receptors [93,94], OX2 dimerization may predominantly involve the C-terminal domain.
In particular, the C-terminus of the variant mOX2 receptor may be similar to that of the δ-opioid
receptor [93]: in which a 15 amino acid C-terminal deletion is also not able to dimerize. This seems
likely, since either human orexin receptor subtype interacts with GPR103, as identified by BRET and
FRET, in a manner similar to that of mOX2 heterodimers. Furthermore, similar to mOX2 heterodimer
signalling through ERK activation, cells co-expressing orexin receptors and GPR103 are noted to
produce ERK1/2 phosphorylation when stimulated by either orexin or the GRP103 agonist, QRFP:
an effect that was blocked by orexin receptor antagonists [68].
Evaluating the physiological relevance of receptor multimers is important. Even though tools
such as selective ligands, membrane-permeant peptides or antibodies can sometimes detect receptor
dimers and oligomers, it is possible that heterodimerization is not always possible. Most importantly,
the differential expression of mOX2α and mOX2β may preclude heterodimerization.
4.2. Evidence for OX1-CRF1 Receptor Dimerization
Our understanding of the interaction between OX1, the CRF1 corticotropin-releasing factor
receptor and the non-GPCR σ1 receptor [95] provides further insight into the mechanisms of receptor
cross-talk. Navarro et al. presented a FRET analysis of the OX1−CRF1 complex to show that it is
subject to cross-antagonism (i.e., the response to agonist of either receptor was blocked by antagonists
towards either receptor). By contrast, activation of each receptor resulted in negative crosstalk between
the receptor responses: despite the fact that activation of each receptor alone stimulated coupling
to β-arrestin and phosphorylation of protein kinase B and ERK1/2. These effects were shown to be
blocked by cell-permeable peptides composed of either the OX1 receptor TM1 or -5 [95].
Evidence of the physiological relevance of the interaction between OX1 and CRF1 was consistent
with dopamine release from ventral tegmental area (VTA) upon orexin-A stimulation: a response
that was inhibited by antagonists of both OX1 and CRF1 receptors, and by CRF itself. When σ1
receptors were stimulated, OX1 and CRF1 receptors were freed from cross-antagonism and negative
crosstalk, suggesting a native OX1−CRF1−σ1 interaction. Upon activation of the σ1 receptors, CRF1
no longer inhibited the OX1-stimulated dopamine release. The total dopamine release was higher
upon stimulation of both σ1 and OX1 receptors compared with stimulation of OX1 receptors alone [95]:
suggesting the physiological and pharmacological significance of the interaction. Collectively, these
results suggest that OX1 receptor complex formation with other receptors, such as the CRF1 or GPR103,
may be very efficient.
4.3. OX1 Orexin Receptor and κ Opioid Receptor (κOR) Heteromerization
Evidence of receptor co-localization suggests the possibility of OX1−κOR receptor
heteromerization that may have clinical relevance. The balance of orexin peptide signalling through
either the OX1 or the OX2 may influence anti-depressant or pro-depressant effects [96]. Physiological
evidence implicates orexins in the regulation of emotion. For example, reduced cerebrospinal orexin
levels and reduced diurnal orexin fluctuations have been reported in patients with depression [97] and
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decreased OX1 activity may worsen depression in a chronic unpredictable mild stress (CUMS) mouse
model [98].
In this context, it is interesting that excessive activation of κOR induces not depression but anxious
and fearful behaviour in both humans and rodents [99]. While the contribution of variant receptors to
these processes is unknown, the system may be regulated by heterodimerization [96] and/or functional
interaction [6]. For example, the putative orexin receptor interaction with κOR may modulate pain,
stress responses and conditions such as addiction, depression, and schizophrenia [100]. These effects
might be indirect. For example, it has been proposed that κOR stimulation inhibits OX1 activation in
dopaminergic neurons [77].
Some studies suggest that the functional interaction occurs purely through an intracellular
signalling pathway in which the OX1 receptor activation enhances c-Jun N-terminal kinase
(JNK)—mediated phosphorylation of κOR. In CHO-K1 cells, this would have the effect of inhibiting
adenylyl cyclase κOR signalling and enhancing its signalling via β-arrestin and p38 MAPK, apparently
via Gq/11 [101]. While this may be consistent with evidence that orexin and dynorphin neuropeptides
negatively regulate one another’s reward pathways through opposing effects in the VTA [102], whether
this is a functionally significant mechanism remains unclear. It is also worth taking into consideration
that essentially all orexinergic neurons co-express dynorphin (though the reverse is not true).
While κOR monomers signal mainly through activation of Gi/o [103], their dimerization with OX1
may result in “opposite” signalling through Gs [77]. Co-localization findings suggest that normal OX1
and κOR homo- and heterodimerization may coordinate signalling responses through the co-release of
peptides in regions such as the hypothalamus [61]. This conclusion is consistent with evidence that
OX1 and κOR co-expression in hippocampal neurons is less extensive in depressed rats than in normal
rats [104]. In this context, it is intriguing that Chen et al. reported that heteromerization reduced
the coupling of OX1 and κOR to Gq and Gi, respectively, while it instigated coupling of the receptor
heteromers to Gs. Taken together, this would elevate cAMP production in HEK293 cells. Similarly,
Li et al. showed that heterodimerization of the apelin receptor and κOR increased cAMP accumulation
after treatment with either class of ligand [76].
Having presented a critical review of the homo- and heterodimerization literature for the orexins
and other systems, such as opioid and CRF1 receptors, we will examine evidence for the functional
interaction of OX1 and the CB1 cannabinoid receptor in the context of its potential clinical relevance.
4.4. Interaction of OX1 Receptors and CB1 Cannabinoid Receptors
The CB1 cannabinoid receptor has been shown to heterodimerize with other class A GPCRs,
including D2 dopamine [85], opioid [105], adenosine A2A [106] and AT1 angiotensin [107] receptors.
In addition to other heterodimerization partners, human OX1 and OX2 receptors have been reported to
heterodimerize with CB1 cannabinoid receptors [60,69]. In contrast to the more discrete hippocampal
expression of the orexins, the widespread expression of the endocannabinoid system in general, and the
CB1 receptor in particular, allows ample opportunity for co-expression of the receptors and interactions
of the systems.
Physiologically, orexins and endocannabinoids may have overlapping functions.
The endocannabinoids, lipid metabolites such as 2-arachidonoyl glycerol (2-AG) and anandamide, are
native ligands of CB1 cannabinoid receptors. They regulate many physiological functions including
analgesia, appetite, learning and memory [108]. Furthermore, orexin receptor signalling may trigger
production of 2-AG, leading to the activation of the CB1 receptor [60,81–83]. In vitro, the human OX1
forms heteromeric complexes with CB1 receptors [67,69,109] that, if present in vivo, may be influenced
by receptor variants. Furthermore, heteromultimerization of CB1 and OX1 receptors has been reported
to be subject to orexin-A feedback involving the both receptors [67].
The data from Jäntti et al. shows that both orexin receptor subtypes are capable of forming
constitutive homo- and heteromeric complexes with one-another and with CB1 cannabinoid
receptors [69]. However, while dimerization is possible, the data suggest that the downstream
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effect on signalling may result as much from a functional interaction than a molecular interaction of
the receptors [60,61,82]. In the case of OX1−CB1 interaction, Jäntti et al. reported that the major
part, if not all, of the interaction results from orexin-promoted 2-AG production and not from
heterodimerization [60]. However, no receptor dimerization-blocking peptides have been used to
assay this interaction.
Using a BRET assay, Jäntti et al. found that CB1 receptors readily homodimerize and
heterodimerize with OX1 and OX2 receptors (Figure 4). Homomeric complexes of OX1, OX2 and
CB1 showed the best BRET efficacy in this study. While the evidence for OX1−CB1 receptor interaction
was similar to that for OX1 and OX2 receptors, the evidence for CB1 and OX2 receptor interaction was
weaker (Figure 4) [69]. When constitutive CB1−OX2 complexes were tested for a possible change upon
orexin stimulation, only a minor (< 10%) reduction in BRET was reported. These studies highlight
the issue of GPCR dimer stability. Since geometry limits the use of FRET or BRET efficiency to assess
affinity for complex formation, different receptor combinations cannot be compared quantitatively.
This is clearly illustrated in Figure 4, which shows that BRET efficiency can vary depending on which
partner of the heteromer harbors which BRET component. While these results establish that such
complexes can be formed, they do not indicate that they are actually present and function in cells
in situ.
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In conclusion, both orexin receptor subtypes and CB1 cannabinoid receptors are capable of
forming constitutive homo- and heteromeric complexes that may be relevant to orexin signalling.
Whether these complexes are physiologically functional and whether they are dynamically regulated,
however, remains to be shown. The so-called bivalent ligands, however, represent a possible way
of determining their physiological significance. Although ligands, such as those designed for the
CB1 receptor dimers [110,111], may show some selectivity for the receptor homo- or heterodimers,
no agonists specific to putative orexin–CB1 heterodimers exist currently. In fact, the data suggest
that the effect of orexin potentiation of CB1 signalling may not result from heterodimerization but,
instead, result from orexin-promoted 2-AG production (see above). The extent to which functional
interactions can explain the putative confluence of orexin and cannabinoid systems better than receptor
heterodimerization is important due to the potential for such an interaction to influence pharmacology.
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5. Relevance of CBl/OX1 Expression in the Hippocampus to Disease
A number of studies have demonstrated molecular and functional cross-talk between CB1 and
OX1 receptors in heterologous expression systems. Evidence of functional crosstalk suggests that
CB1-OX1 interaction may take place in the neuronal membranes at nerve terminals in many brain
regions. This is especially true in the hippocampus [112], where co-expression of CB1 and OX1 is in
evidence. In view of this, changes in CB1/OX1 expression may be a biomarker for CNS disease in
certain brain regions.
Recently, the problem of pharmacoresistance in status epilepticus (SE) has generated interest in
developing novel pharmacological interventions that will limit the damage that develops as seizure
duration increases during pharmacoresistance [113,114]. This is not only the case for traditional
benzodiazepine drugs, since over 40% of SE cases are refractory to initial treatment with two or more
medications [113]: rendering SE a life-threatening neurological condition.
Safety concerns have historically led to restrictions in the medicinal use of marijuana [115].
In some recent studies, however, cannabinoids have been implicated in epileptogenesis. While
∆9-tetrahydrocannabinolic acid (THC) itself may be proconvulsant under some circumstances,
the efficacy of drugs such as cannabidiol (CBD), that do not primarily target CB1 receptors [4],
suggests the therapeutic potential of cannabinoids. Physiological studies suggest that endogenous
cannabinoids in the hippocampus act as retrograde messengers from depolarized postsynaptic neurons
to presynaptic terminals [116]. This may result in depolarization-induced suppression of inhibition
(DSI); although homo- and heterosynaptic depolarization-induced suppression of excitation (DSE),
and cannabinoid-mediated plasticity are also possible.
In human subjects, downregulation of CB1 receptors has been reported in epileptic hippocampal
tissue [117]. Consistent with this, Falenski et al. found reduced CB1 levels in the rat hippocampus
following SE in the pilocarpine model [118]. However, Bojnik et al. found an elevation in CB1
expression in the kainic acid model [119] that may be consistent with evidence that CB1 agonists
protect against the excitotoxic injury induced by kainic acid [120].
There is evidence that, at least under some circumstances, orexinergic neurons are under
the control of presynaptic CB1 receptor-regulated inputs [78,121]. The long-term effects of kainic
acid-induced SE on CB1 and OX1 expression in rat hippocampus has been examined. CB1 expression
in the hippocampus increased after SE, as measured by immunohistochemistry and RT-PCR [112].
However, Zhu et al. did not report an increase in OX1 expression after SE: an observation that may
reflect the fact that antibodies to OX1 do not always perform well (personal observations). Although it
is doubtful that, even with further testing, THC or the present generation of orexinergic drugs would,
themselves, be useful as anticonvulsants, changes in putative CB1/OX1 interaction may reflect CNS
pathogenesis that may be relevant to pharmacology.
By contrast with the cannabinoids, data showing the seizure-modulating role of orexins are still
emerging. For example, Doreulee et al. reported the possible involvement of the orexinergic system in
antiepileptic mechanisms [122]. On the other hand, other studies have reported behavioural seizure
activity when orexin peptides were injected ICV into rats [29].
The overlap in CB1 and OX1 distribution in nerve terminals of the hippocampus may be worth
examining with respect to its potential to influence heterodimer formation and epileptogenesis [112].
However, alternative explanations may include the following: (1) The OX1/CB1 heterodimers in
SE merely represent biomarkers that may be of limited specificity in SE or its treatment; and
(2) The OX1/CB1 heterodimers in SE have relevance as novel therapeutic targets, although they
do not necessarily reflect the pathobiology of SE. CB1 and OX1 “cross-talk” in SE, however, may only
become clinically useful with the development of novel drugs that target either OX1 or CB1.
6. Conclusions
This discussion focuses on an examination of the evidence suggesting that orexin receptor
signalling can result from functional interaction and/or homo- and heterodimerization with opioid
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and cannabinoid systems. We presented perspectives on orexin signalling in the context of other
neurotransmitter systems implicated in epilepsy and neurodegeneration that could be informative to
future work.
Human OX1 orexin receptors have been shown to homodimerize and interact functionally with
other receptor types. In particular, the evidence for heterodimerization versus functional interaction for
OX1 and κOR and the CB1 cannabinoid receptors is discussed. While dimerization may be important
for orexin receptor responses and trafficking, many physiological effects can be explained through the
evidence for functional interactions (i.e., interactions of receptor signal transduction pathways). In this
regard, we assess evidence suggesting that orexin receptor activation can result in endocannabinoid
production that acts at CB1 receptors.
By contrast, dimerization may be a means whereby signalling is optimized for a given receptor
type. For example, complexes may form when optimal cannabinoid concentrations are available for
cannabinoid receptors. While orexin receptor subtypes readily form homo- and heteromeric complexes,
as suggested by significant BRET signals, it would be unclear whether this takes place in situ except
for the few studies have assessed this phenomenon [95]. As a result, ex vivo preparations may be a
useful means of examining this in future studies.
The pharmacology of the known orexin receptor variants, especially those located in the carboxyl
terminal, such as OX1408 and OX2401 (Tables 1 and 2), are discussed in the context of GPCR signalling;
however, their potential impact on orexin receptor homo- and heterodimerization is not known. Since
co-expression of OX1 and OX2 receptor variants is relatively common, however, their functional
significance is discussed. Given that state of the present knowledge it is unclear if co-expression results
in, A. distinct pharmacology through functional interaction, B. distinct pharmacology as a result of the
formation of variant heteromers, or C. no change in pharmacology.
The structural insights resulting from resolving the orexin receptor crystal structure [39–41] may
clarify many points discussed. To further this endeavor, we contrast evidence supporting the functional
interaction versus the heterodimerization hypotheses of orexin receptor interaction with other systems
such as cannabinoid receptors. The potential of these interactions to enhance the pharmacological
treatment of some neurological conditions such as epilepsy and depression is noted.
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